Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Expert Opin Biol Ther. 2014 Apr 29;14(9):1241–1257. doi: 10.1517/14712598.2014.915307

Figure 3. Therapeutic targets to enhance antitumor immunity using Ad vectors.

Figure 3

FLT3L drives the generation of myeloid and lymphoid derived DC populations. CD40L enhances the expression of co-stimulatory ligands such as CD86/CD80 on DCs and also stimulates the release of cytokines including IL-12, IL-18 and RANTES/CCL5. IL-12 promotes the development of CD4+ TH1 cells and the release of IFN-γ and IL-2 by CD8+ T cells and NK cells, thus increasing cytotoxicity against tumor cells. IFN-γ and IL-2 also play a role in the generation of memory T cells. Additionally, IFN-γ enhances MHC I expression on tumor cells and facilitates their recognition by CD8+ T cells. APC: antigen presenting cell, Ad: adenovirus, DC: dendritic cell, TCR: T cell receptor; Antigen.